LENZLENZ Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of LENZ Therapeutics, Inc. against Biological Products, (No Diagnostic Substances) — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LENZEsta | $127M#10 | — | 0.6x#2 | 6.7x#5 | — | -65.0%#10 | -477.5%#5 | -37.5%#5 | — | — | -90.3%#14 | — |
| OTLK | $164M#3 | — | — | 115.7x#8 | — | 17.2%#6 | -4744.3%#7 | — | -12.8%#1 | — | -32.5%#7 | — |
| HUMA | $161M#4 | — | 5.2x#10 | 79.1x#7 | — | 72.5%#3 | -5306.0%#8 | -130.6%#9 | — | — | -67.8%#12 | — |
| ARMP | $155M#5 | — | — | — | — | -818.8%#14 | — | — | — | — | 41.5%#2 | 0.1%#1 |
| TNYA | $151M#6 | — | 2.2x#5 | — | — | 18.5%#5 | — | -130.5%#8 | — | — | -48.9%#10 | — |
| CRBU | $140M#7 | — | 1.4x#4 | 12.5x#6 | 11.7%#1 | 0.7%#7 | -1329.4%#6 | -151.0%#10 | — | — | -26.3%#4 | — |
| NMRA | $136M#8 | — | 3.1x#7 | — | — | -2.8%#9 | — | 532.2%#2 | -594.0%#2 | — | -53.8%#11 | — |
| ENGN | $128M#9 | 0.8x#1 | 0.6x#1 | — | — | -112.7%#11 | — | -50.9%#6 | — | — | -72.6%#13 | — |
| BDTX | $112M#11 | — | 1.2x#3 | 1.6x#2 | — | 132.1%#2 | 17.9%#2 | 23276.9%#1 | — | — | -41.7%#9 | — |
| CRDF | $107M#12 | — | 4.0x#9 | 179.7x#9 | -13.2%#3 | -0.9%#8 | -8256.3%#9 | -0.2%#3 | — | — | -36.6%#8 | — |
| CGTX | $100M#13 | — | 3.0x#6 | — | — | 30.9%#4 | — | -71.1%#7 | — | — | -28.3%#5 | — |
| ATTO | $1.0B#1 | — | — | — | — | — | — | — | — | — | 323.7%#1 | — |
| ATRA | $98M#14 | — | — | 0.8x#1 | -6.3%#2 | 138.3%#1 | 29.7%#1 | — | — | — | -18.3%#3 | — |
| BSEM | $87M#15 | — | 3.1x#8 | 1.8x#3 | -31.8%#4 | -121.2%#12 | -1.5%#3 | -23.8%#4 | — | — | — | — |
| PTHS | $86M#16 | — | — | 5.1x#4 | — | -444.6%#13 | -193.1%#4 | — | — | — | -28.7%#6 | — |
| SCTX | $623M#2 | — | — | — | — | — | — | — | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-20.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice